Federal advisers to the Centers for Disease Control and Prevention are preparing to vote Thursday and Friday on whether to remove or delay the long-standing recommendation that every newborn receive a hepatitis B vaccine within 24 hours of birth. The birth dose, adopted widely in the early 1990s, is credited with a roughly 99 percent drop in acute pediatric hepatitis B cases and is estimated to have prevented more than 6 million infections and nearly 1 million hospitalizations. The proposal arrives amid recent leadership changes and staff turnover at the CDC and has reignited debate between clinicians emphasizing individual risk assessment and public health authorities who warn that delaying the birth dose would increase chronic infections in exposed infants.
Key takeaways
- The hepatitis B birth dose has been standard U.S. practice since the early 1990s and is associated with an approximately 99% reduction in acute pediatric hepatitis B cases.
- An independent review by the Vaccine Integrity Project reported that birth dosing helped prevent more than 6 million infections and nearly 1 million hospitalizations, though that report is not peer-reviewed.
- The Advisory Committee on Immunization Practices (ACIP) will meet Thursday and Friday to consider changing the recommendation; ACIP recommendations strongly influence insurance coverage.
- Without vaccination, about 90% of infants exposed at birth develop chronic hepatitis B, according to the American Academy of Pediatrics.
- A 2019 report found 84%–88% of pregnant women were tested for hepatitis B, leaving a meaningful share without documented prenatal screening.
- Dr. Kirk Milhoan, an ACIP member since June and named ACIP chair this week, has urged individualized clinician assessment rather than a universal birth dose policy.
- The meeting agenda posted online provides broad topics but lacks detailed speaker listings or data presenters as of Tuesday.
Background
Hepatitis B is a bloodborne and sexually transmitted virus that can be passed from mother to infant during childbirth. Perinatal transmission frequently leads to lifelong infection: infants exposed at birth progress to chronic hepatitis B roughly 90 percent of the time without prophylaxis. To prevent mother-to-child transmission, U.S. public health authorities adopted a universal newborn dose in the early 1990s, a policy credited with sharply reducing pediatric acute infections.
The Advisory Committee on Immunization Practices, a federal advisory group that issues recommendations later considered by the CDC director, is the forum for debating vaccine policy. In recent months the CDC has undergone organizational upheaval, including leadership changes and a wholesale replacement of ACIP members in June by appointees of Health Secretary Robert F. Kennedy Jr., which has altered the committee’s composition and prompted renewed scrutiny of established vaccine recommendations.
Main event
The ACIP is scheduled to deliberate this week on whether to eliminate or postpone the hepatitis B birth dose, including consideration of delaying the first shot by a month or two. The agenda posted publicly offers only high-level descriptions and does not identify who will present new data, leaving observers uncertain about the evidence base that will be discussed. A planned vote in September was tabled amid committee confusion, and members now face a renewed decision with potential implications for insurance coverage and hospital protocols.
Proponents of keeping the birth dose point to decades of surveillance data and reviews that find no short- or long-term harms tied to the infant vaccine. Public health experts stress that missing or delayed vaccination would leave infants whose mothers were not tested or who did not disclose risks vulnerable to chronic infection. Opponents and some new ACIP appointees argue that the day-one shot can trigger neonatal fever and downstream interventions such as blood draws, and therefore that clinicians should weigh individual maternal risk when deciding whether to vaccinate immediately.
The debate is complicated by the mix of evidence and the provenance of new analyses. An independent group led by the Center for Infectious Disease Research and Policy at the University of Minnesota published a review this week concluding substantial public-health gains from the birth dose, but that report has not undergone peer review. Meanwhile, officials have signaled discussion of other vaccine topics at the meeting, including aluminum adjuvants and their safety profile, further broadening the committee’s agenda.
Analysis & implications
Altering the birth-dose recommendation could produce measurable increases in chronic hepatitis B if exposed infants are not promptly protected. Because a significant minority of pregnant people are not screened or may not disclose risk behaviors, a universal birth dose functions as a safety net that reduces reliance on complete prenatal screening and on accurate disclosure. If the ACIP recommends removing the universal mandate, hospitals and pediatricians would face operational changes and potential liability concerns while insurers may reinterpret coverage, which can affect uptake.
Policy change could also have broader effects on vaccine confidence. Revisiting a long-established childhood vaccine in a context of high-profile CDC turnover risks amplifying public uncertainty even if a decision is framed around targeted risk-based care. Public health communicators would need to make a clear case for any new approach and describe safeguards to prevent newborn exposure from slipping through screening gaps that currently exist.
From a global perspective, U.S. practice influences recommendations and perceptions abroad; a shift away from the birth dose could be referenced by international advocates of delayed schedules and might erode years of progress in perinatal hepatitis B prevention. Conversely, if ACIP bases a change on robust new data demonstrating net benefit of a screened, risk-based approach, it could prompt investments in prenatal screening systems that reduce the need for a universal birth dose. At present, the evidence presented publicly is incomplete, increasing uncertainty about downstream outcomes.
Comparison & data
| Metric | Pre-birth-dose era | With birth-dose policy |
|---|---|---|
| Acute pediatric hepatitis B | Higher incidence | ~99% reduction |
| Estimated infections prevented | — | >6,000,000 (Vaccine Integrity Project review) |
| Estimated hospitalizations prevented | — | ~1,000,000 (Vaccine Integrity Project review) |
| Risk of chronic infection if exposed at birth | ~90% of infants | Substantially reduced with timely vaccination |
The table summarizes figures cited during public discussion: the 99 percent reduction in acute pediatric cases and the Vaccine Integrity Project’s estimates of infections and hospitalizations prevented. Those estimates rest on aggregated surveillance and modeling; the cited review was not peer-reviewed and should be weighed alongside published, peer-reviewed evidence and real-world surveillance data before changing policy.
Reactions & quotes
Supporters of the universal birth dose emphasize decades of population-level data showing dramatic reductions in pediatric hepatitis B and point to the birth dose as a critical last line of defense when prenatal screening is incomplete.
Day-one vaccination has a risk of neonatal fever that can prompt additional interventions and testing.
Dr. Kirk Milhoan, ACIP member and chair
Dr. Milhoan has urged individualized clinician assessment of newborn risk and has questioned whether the universal birth dose should remain mandatory in all deliveries. His comments reflect a broader view among some new ACIP appointees that clinical judgment and maternal screening can guide targeted dosing.
I have never seen a serious reaction after thousands of babies received the hepatitis B vaccine, and I did not observe fever associated with the shot.
Dr. Sean O’Leary, pediatric infectious disease expert and AAP spokesman
Dr. O’Leary and other pediatric infectious disease specialists argue the safety record supports maintaining the birth dose, stressing that adverse events are rare and that delaying vaccination risks allowing preventable chronic infections.
Unconfirmed
- The Vaccine Integrity Project review cited many prevented infections and hospitalizations but has not been peer-reviewed, leaving some methodological questions unresolved.
- A recent internal FDA memo attributing at least 10 child deaths to Covid vaccines was circulated without publicly presented evidence and remains unverified.
- It is not yet confirmed which external researchers or datasets will be presented at the ACIP meeting, or whether the committee will vote to eliminate the birth dose or delay it by a specific interval.
Bottom line
The ACIP deliberation this week is a consequential reassessment of a decades-old public-health policy. Keeping or removing the universal hepatitis B birth dose will have immediate implications for newborn protection, insurance coverage and the structure of prenatal screening and vaccination workflows in hospitals and clinics across the country.
Given gaps in prenatal testing and the high probability that exposed infants develop chronic infection without timely vaccination, public-health authorities caution that any change should be based on comprehensive, peer-reviewed evidence and accompanied by robust systems to ensure mothers are screened and infants at risk are identified and vaccinated promptly. Observers should watch the ACIP meeting closely for the data presented, the reasoning of committee members, and the CDC director’s subsequent decision.
Sources
- NBC News — mainstream news report on ACIP deliberations and interviews with clinicians and experts.
- Centers for Disease Control and Prevention — U.S. federal public health agency, reference materials on hepatitis B and vaccination policy.
- American Academy of Pediatrics — professional pediatric association, guidance on perinatal hepatitis B and infant vaccination.
- Vaccine Integrity Project (CIDRAP) — independent group report cited for estimates of infections and hospitalizations prevented (non–peer-reviewed).